The mechanism of Supplemented Liang Xue Xiao Feng Powder(SLXXFP) adjusting blood-heat syndrome psoriasis vulgaris(PV) apoptosis by miR-203-SOCS3-JAK2/STAT3 double-inhibitory pathway
Phase 1
Recruiting
- Conditions
- Psoriasis Vulgaris
- Registration Number
- ITMCTR2000004112
- Lead Sponsor
- Hospital of Chengdu University of Traditional Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1. Meet the diagnosis of PV;
2. A diagnosis of blood-heat syndrome;
3. Aged 18 to 70 years;
4. Voluntarily participate in this study; Ability to sign informed consent; Agree to accept the treatment.
Exclusion Criteria
1. With other skin diseases;
2. With other Severe systemic chronic wasting disease;
3. With mental disease;
4. Received systemic glucocorticoids, retinoids or methotrexate medication within a month, or who received topical glucocorticoids within 2 weeks;
5. Scar diathesis.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method